Guggenheim cuts Universal Health Services stock price target to $201 on weak Q3

Guggenheim reduced its price target for Universal Health Services (UHS) to $201 from $209, citing weak Q3 2026 EBITDA and macro pressures. UHS stock is down 8.5% in a week. The company lowered its 2026 EBITDA guidance but sees potential upside from expansions. UHS reported Q3 EPS of $5.22 and revenue of $4.73B, slightly beating estimates. Raymond James kept a Market Perform rating, noting softer profit trends and a cautious 2027 outlook.

Original reporting
Published Oct 29, 2026, 11:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 12:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$UHS
Bearish
medium confidence
Mentioned
$UHS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$UHSBearishMed
01

Why it matters

The downgrade suggests near‑term downside risk, but long‑term fundamentals may still be attractive.

02

Market read

UHS price target cut could trigger short‑term selling pressure, influencing healthcare service stocks.

03

What to watch

Potential upside from de‑novo facility maturation and synergies not yet reflected in the price.

Relevance 7/10Novelty 7/10Timing: today

Background

Guggenheim analysts revised UHS's valuation after the company's third‑quarter earnings and updated guidance.

Company-level read

Ticker impact

$UHSBearishMedium confidence
Context

Guggenheim lowered its price target on Universal Health Services to $201, citing weak Q3 results and reduced 2026 EBITDA guidance.

Expected impact

likely pressure as the market prices in the guidance downgrade and lower target.

Evidence & confidence

The new target reflects weaker earnings and guidance, which typically prompts sell‑offs.

Market effects

May weigh on the broader healthcare services sector as peers could face similar valuation pressure.

Limited to U.S. markets where UHS trades.

Low, as the news is company‑specific.

Counterpoint

If the Q3 beat and cash flow remain strong, the target cut could be an overreaction.

Key entities

  • Universal Health Services

    U.S. healthcare services provider (ticker UHS).

  • Guggenheim

    Equity research firm that issued the price‑target cut.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$CNCMed

Health insurers, hospitals rally after sweeping midterm win for Democrats

Shares of Medicaid-focused health insurers (Centene, Elevance, Molina) and hospital operators (HCA, Tenet, Universal) rose after Democrats won the midterms, raising hopes for sector-friendly policies. Analysts expect delays in Trump's OBBBA, easing pressure on Medicaid and ACA insurers, and potential extensions of enhanced subsidies. Year-to-date gains vary among companies.

$UHSHighAI 8/10

Softer surgery volumes, hospital woes dampened UHS’ Q3 earnings

Universal Health Services (UHS) lowered its 2026 earnings expectations due to declining surgeries and struggles at some hospitals. Q3 net income fell 17% to $308M, while revenues rose 5% to $4.7B. Challenges include lower surgery volumes, delays in new hospital profitability, and rising uninsured patients. UHS expects to be at the lower end of its guidance range for 2024.

$UHSMedAI 8/10

Raymond James reiterates Universal Health Services stock rating

Raymond James maintained a Market Perform rating on Universal Health Services (UHS), citing Q3 results slightly below expectations and a cautious 2027 outlook. UHS stock is down 21% YTD, trading at $172.18. Analysts have lowered earnings estimates due to slower growth at new facilities. Despite near-term challenges, UHS is trading at a P/E ratio of 6.89, suggesting potential undervaluation.